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Investigational drug approaches Recent progress has reshaped the clinical landscape in the 
treatment of MPM. We have now more effective chemotherapy and from current evidence, 
it is clear that histone deacetylase inhibitors represent a potentially new treatment 
modality in MPM. Among current investigational drugs, mesothelin targeted therapies, 
dendritic cell based immunotherapy and gene therapy hold promise and should be further 
explored. Despite these, actual treatment is still amenable to improvement. Several factors 
have hampered the development of more effective regimens for mesothelioma. MPM is 
uncommon, is heterogeneous, staging is unreliable, response assessement is difficult and 
most drugs do not work. For the staging, the International Mesothelioma Interest Group 
are actually collaborating with the IASLC to include malignant pleural mesothelioma in 
its proposals for the 8th edition of TNM classification. The ability to measure reproducibly 
tumour response to treatment is vital in the development of new drugs and therapeutic 
combinations, particularly for the conducting of phase II studies. Conventional response 
criteria have always been difficult to apply to malignant mesothelioma due to its unique 
pattern of growth. Because the selection of measurement sites in mesothelioma is difficult, 
RECIST criteria could be applied differently by different investigators and that’s why the 
Modified RECIST criteria have been developed. Based on the complex growth pattern 
of MPM, response evaluation in this cancer entity is still challenging. Results on value 
of fluoro-2-deoxy-D-glucose and positron emission tomography imaging ((SUVmean, 
tumor lesion glycolysis (TLG) and tumor volume (PETvol)) in response assessment in 
MPM are promising. Where do we go from here with the systemic therapy for MPM? We 
need better drugs, probably by more accurate preclinical investigation and we have to use 
better the drugs we have: in maintenance therapy, in special populations, in multimodality 
setting. More selectivity regarding the “promising” drug we choose to move from the 
bence to the clinic and fewer “me too” trials are warranted. Better designed trials that 
are adequately powered, multicenter, preferable with randomized phase II design to 
balance for heterogeneity, with appropriate endpoints (PFS, OS, QoL) and with correlative 
studies built in, are mandatory. Methods to assay individual tumor characteristics are 
warranted in order to avoid toxicity in patients who may not respond to treatment and 
losing precious time in a disease associated with a short survival. Drug resistance profiles 
have been reported to various malignant diseases including NSCLC, SCLC, breast, 
ovarian, colon, esophageal and carcinoid tumours. Recently the feasibility of performing 
off-site in vitro drug resistance assays on resected mesothelioma specimens is reported. 
For clinical implementation, a chemoresistance test applicable to pemetrexed should be 
useful. The effectiveness of assay-directed therapy is promising and need to be addressed 
in prospective trials. Multiple biologicals have been studied or are still under investigation, 
however a lot of them seems to fail. It is of great importance that the molecular biologic 
research should focus more on mesothelioma-specific pathways and biomarkers, instead of 
copying mechanisms and treatments that were successful in other tumour types. Looking 
at the list of new VEGFR-inhibitors being tested in MPM, one can question if it is a wise 
use of the limited patient resources to perform so many “me too” trials in this uncommon 
disease? One can question whether trials with so-called targeted agents in an unselected 
population of mesothelioma patients are appropriate. Investigational surgical approaches 
The role of surgery remains controversial and should be further explored. Although the 
multimodality treatment procedure seems feasible, overall treatment time is long and 
psychological distress is considerable. Subgroup analysis of a large Scandinavian phase 2 
combination chemotherapy trial shows a median overall survival of 22 months in patients 
with good performance status, epithelioid subtype, stage I–II and aged 70 years or less, 
equivalent to survival in patients subjected to multimodality treatment. These findings 
stress the importance of a large prospective multicentre, in which operable patients 
with early stage resectable MPM are randomly assigned to a surgical and a non-surgical 
management. The feasibility of this approach has been explored in the UK MARS 1 trial, in 
which the randomisation is between EPP followed by PORT and any palliative treatment, 
including pleurodesis, following an induction treatment with chemotherapy. The results 
of the feasibility part of this trial have recently been released and show no difference in 
survival between both treatment arms. A large retrospective uncontrolled series reports 
that P/D might prolong survival as compared to EPP and that a less invasive procedure 
might hence be preferable in selected patients, provided it is standardised. In a systematic 
review of 1270 patients who had undergone lung-sparing surgery for mesothelioma, overall 
survival was comparable with the outcome reported in historical series including EPP. It 
is expected that a large European multicentre randomised trial will be conducted in the 
coming years, addressing the role of any tumour resection in MPM. Whether the latter will 
include EPP remains to be determined. Investigational radiotherapy approaches The role 
of PORT in MPM is controversial and based on a single uncontrolled retrospective series. 
This additional value of PORT is being addressed in an on-going Swiss study, in which 
eligible patients are randomised after EPP between observation and hemi-thoracic PORT. 
Pleural IMRT allows administering a radical dose of radiotherapy to a MPM with intact 
lung. The role of IMRT with chemotherapy is presently being investigated in patients with 
unresectable disease. Currently a study that looks at whether giving a short intense course 
of chest radiation just prior to surgery will sterilize these tumour cells and thus, avoid or 
reduce contamination of the areas outside the chest cavity is ongoing. The investigators 
hypothesize that short neo-adjuvant (pre-operative) hemi-thoracic IMRT, followed by 
immediate planned extra-pleural pneumonectomy (EPP) (+/- adjuvant chemotherapy) will 
reduce the risk of intra-operative seeding and reduce the incidence of distant metastatic 
disease. Another trial explores the use of tomotherapy to treat mesothelioma more 
aggressively than has been possible before. Tomotherapy’s ability to treat unusual shaped 
tumours, particularly when they are wrapped around sensitive normal tissues (the lung), 
enable higher doses of radiation to be used and this may improve its effectiveness. 
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MEDICAL TREATMENT OF BONE METASTASES (BM) FOR LUNG 
CANCER: CURRENT STATUS AND PERSPECTIVES
Christian Manegold  
Chirurgische Klinik - Interdisziplinäre Thorakale Onkologie, Medizinische Fakultät 
Mannheim Der Universität Heidelberg, Mannheim/GERMANY
Clinical relevance of BM: Bone metastases are a major source of morbidity for patients 
with solid tumors (Coleman, Clin Cancer Res. 2006). They can decrease the mobility 
and the performance status, and may contribute to arrosion in quality of life for patients 
with lung cancer. Bone metastases are the most common cause of potentially debilitating 
pain (Mercadant, Pain, 1997). Because bone metastases are associated with a loss in bone 
structure integrity, they increase the risk of pathologic fractures, with the consequence of 
surgical or radiological interventions (Saad et al, Cancer, 2007). The incidence of skeletal-
related events (SREs) is becoming a greater concern in the lung cancer setting as patients 
life are extended by advances in antineoplastic treatment strategies (Tsuya et al, Lung 
Cancer, 2007). Each typ of SRE is associated with decreases in function and quality-of 
life. Moreover, pathologic fractures and spinal cord compression can result in prolonged 
convalescence or permanently impaired mobility and can be associated by depression 
and anxiety. Also bone metastases can be the first manifestation of lung cancer in a 
small percentage of patients, up to 40% of patients with advanced lung cancer developed 
bone metastases during the course of their disease (Coleman, Clin Cancer Res. 2006; 
Kagohashi et al, Int J Clin Pract, 2003). 
 
Current management of BM: Currently, treatment of BMs from solid tumors 
including lung cancer, mainly of palliative nature, involves radiation to bone, surgery, 
analgesics and bisphosphonates (Serafini, J Nucl Med, 2001). Multiple generations of 
bisphosphonates have been developed, each with different strength for inhibiting bone 
resorption. Early-generation nitrogen containing bisphosphonates such as pamitronate, 
elentronate, and ibantronate may provide transient palliation of bone pain, but may 
not provide objective long-term clinical benefit (Lipfon, J Support Oncol, 2004). The 
bisphosphonate zoledronic acid, a new-generation high-potential bisphosphonate has 
demonstrated broad clinical utility in managing malignant bone disease from a variety of 
solid tumors and has received international regulary approach (Lipton et al, Clin Cancer 
Res, 2004; Theriault, Expt Rev Anticancer Ther, 2003). Bisphosphonates are, however, 
associated with nephrotoxicity (Rosen et al, Cancer, 2004), which requires monitoring 
and may nessitate initial dose adjustment and withholding of doses. Therefore, combining 
of bisphosphonates with commonly used platinum-based chemotherapy as first-line 
treatment of advanced NSCLC is complicated by the overlapping renal safety profile of the 
two strategies. 
 
A new, innovative option for the management of BM: The receptor activator of nuclear 
factor-kapa B (RANK) and osteoprotegerin (OPG) axis plays a key role in maintaining 
normal bone homeostasis (Fuller et al, J Exp Med, 1998; Lacey et al, Cell, 1998; Lacey et 
al, Am J Pathol, 2000). In preclinical studies, it has been shown that tumor cells induce 
elevated levels of RANK ligant (RANKL) that increase osteolytic activity (Fizazi et al 
Clin Cancer Res, 2003). Denosumab (XGEVA) is a fully humanized monoclonal antibody 
against RANKL (Mc Clung et al, N Engl J Med, 2006). 
It is not cleared by the kidney and is therefore not associated with the same problems 
as bisphosphonates in patients with renal impairment. Denosumab’s safety profile 
estabilished in the large number of patients with advanced solid tumors indicate 
infrequent osteonecrosis of the jaw rates similar to zoledronic acid, clearly fewer acute 
face reactions compared to zoledronic acid, an increase of hypocalcaemia which is not 
associated with symptoms and/or clinical sequelae (Stopeck et al, J Clin Oncol, 2010; 
Fizazi et al, Lancet, 2011; Henry et al, J Clin Oncol, 2011). Denosumab has received 
approval for the prevention of SREs in patients with solid tumors and bone metastases. 
Data from three randomized phase III-denosumab trials conducted in breast cancer, 
prostate cancer, and other solid tumors – including lung cancer - or multiple myeloma 
have been combined in a preplanned integrated analysis(Stopeck et al, J Clin Oncol, 2010; 
Fizazi et al, Lancet, 2011; Henry et al, J Clin Oncol, 2011). Here, patients were equally 
randomized to receive either a monthly subcutaneously denosumab injection (120 mg) 
or intravenous zoledronic acid (4 mg; dose adjusted for renal function). Daily calcium 
and vitamin D supplements were recommended. These analysis has demonstrated that 
denosumab is superior in the prevention of SREs over zoledronic acid by significantly 
prolonging time without SRE, and significantly reducing the SRE’s rate overall. 
Furthermore, this analysis has established denosumab’s safety profile in about 6000 
patients with advanced solid tumors. 
 
The lung cancer subset of the solid tumors/myeloma trial (Henry et al, J Clin Oncol, 2011) 
was separately further investigated by an exploratory analysis assessing overall survival 
for denosumab in comparison to zoledronic acid. A total of 811 patients with lung cancer 
(702 NSCLC; 109 SCLC) were enrolled. The median age of that patients was 61 years, most 
were males and Caucasians. About 90% of patients in both treatment groups received 
prior chemotherapy. More denosumab than zoledronic acid patients had an ECOG status 
of 0 or 1. Overall survival was significantly prolonged with denosumab over zoledronic 
acid in patients with advanced NSCLC and SCLC . Overall survival was not effected 
by prior chemotherapy or differences in ECOG status between the groups. Adverse 
events (AEs) rates were similar between groups. Serious AEs occurred less frequently 
with denosumab than with the zoledronic acid. Osteonecrosis of jaw was balanced, and 
hypocalcaemia appeared more often under denosumab than under zoledronic acid. 
 
Denosumab’s effect on bone metastases in solid tumors including lung cancer 
– conclusion: Denosumab clearly represent a new and innovative option for the 
management of bone metastases. Denosumab offers more benefit than zoledronic acid in 
terms of: a. significantly prolonging time without SRE, regardless of previous SRE history; 
b. consistently favours risk reduction in time to first SRE across tumor types; c. leading to 
significantly fewer SREs across different tumor types; d. significantly prolonging overall 
survival in advanced NSCLC and SCLC. Furthermore, because of denosumab’s favourable 
safety profile and not being nephrotoxic, combining denosumab with standard platinum-
based chemotherapy is not compromised by dose adjustment and dose reduction. 
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SKIN TOXICITY
Yoichi Moroi  
Department Of Dermatology, Graduate School Of Medical Science, Kyushu University, 
Fukuoka/JAPAN
Anti-epidermal growth factor receptor treatment strategies, i.e. epidermal growth 
factor receptor (EGFR) small molecule tyrosine kinase inhibitors, such as erlotinib 
and gefitinib, or monoclonal antibodies such as cetuximab and panitumumab, have 
expanded the treatment options for different tumor types, including head and neck, 
breast, colorectal cancers, pancreatic, and lung. The most clinically significant toxicity 
associated with the use of these EGFR inhibitors (EGFRI) is a papulopustular (also 
referred to as acneiform) rash that affects the face and upper body and develops 
in up to 90% of patients. EGFRI-mediated dermatologic side-effects also include 
hyperpigmentation, xerotic skin, pruritus, skin fissures, periungual inflammation and 
nail changes, disorders of mucous membranes, eyes and hair—with an incidence ranging 
from 49% to 100% of patients. However, it has not thought to be very important, because 
a systematic review of published data from 8998 cancer patients treated in prospective 
clinical trials concluded that there are no reported deaths from skin rash. This skin 
toxicity now is recognized to have a negative impact as it relates to quality of life, 
cost, secondary infections, and the ability to maintain antineoplastic therapy without 
interruption, all of which may also affect clinical outcome. In skin, EGFR is primarily 
expressed in basal and suprabasal keratinocytes, sebocytes, and the outer root sheath of 
the hair follicle, and involves keratinocyte proliferation, differentiation, migration, and 
survival. The mechanisms responsible for this skin toxicity, however, remain unclear. 
Almost all available studies addressing EGFR-inhibitor induced skin rash suggest that 
its severity is a suitable surrogate marker for efficacy of anti-EGFR therapy. Many reports 
observed significant correlation between cutaneous toxicity and objective response rate. 
Therefore, adequate control of adverse effects in the skin is necessary and thereby will 
contribute to prolonged treatment time for cancer patients who respond to EGFR-I. 
In this session, I would like to introduce our experiences, such as a support team for 
patients using specific critical path and the clinical use with 0.1% adapalene gel (Differin 
gel®) for acneifrme eruption and periungual inflammation [1,2]. The specific critical 
path has contributed the understanding the skin care for this treatment of not only the 
patients but also surrounding clinical staff. Finally I will present a basic physiological 
data of the patient’s skin, such as skin capacitance (which indicates skin hydration or 
water volume in the stratum corneum) and analysis of skin surface lipid after initiating 
EGFRI treatment. Our pilot study revealed that skin hydration decreased immediately 
after starting EGFRI therapy, and skin surface lipid gradually increased during its 
treatment. These information will help to establish standard guidelines for skin toxicity 
of anti-EGFR treatment. 
 
1) Hachisuka J, Yunotani S, Shidahara S, Moroi Y, Furue M. Effect of adapalene on 
cetuximab-induced painful periungual inflammation. J Am Acad Dermatol. 2011; 64(2): 
e20-21. 
2) Hachisuka J, Doi K, Moroi Y, Furue M. Successful treatment of epidermal growth 
factor receptor inhibitor-induced periungual inflammation with adapalene. Case Rep 
Dermatol. 2011; 3(2): 130-136.
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NEW DRUG IN PHASE I: RECENT RESULTS AND THE STATUS IN 
JAPAN
Tomohide Tamura  
Department Of Thoracic Oncology, National Cancer Center Hospital, /JAPAN
Development of new drug is essential for the improvement of therapeutic results 
in advanced cancer. New drug development in Japan has been behind the Western 
countries. One of the main reasons for it is “LOCAL” development in Japan. Japanese 
authority required the original study conducted in Japan for only Japanese patients. And 
we had a limited capacity to evaluate new drugs. So, first-in-human phase I studies were 
always conducted in the US or EU, and in Japan we had conducted compact “REPEAT” 
phase I studies of only promising drugs to confirm the feasibility of the Western 
recommended dose for Japanese patients. However, recently, some institutions in Japan 
establish special unit for phase I study, and conduct a lot of phase I studies of new drugs 
including several first-in-human studies to be a member of global development.. A large 
number of new drugs for various targets including driver gene alterations are introduced 
into clinical development. In this presentation, recent results of phase I studies of new 
drugs, and also the current status of phase I studies in Japan, are reviewed.
Keywords: phase I study, new drug
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PHASE II DRUG DEVELOPMENT IN NON-SMALL CELL LUNG 
CANCER (NSCLC)
Primo Lara  
Davis Comprehensive Cancer Center, University Of California, Sacramento/CA/
UNITED STATES OF AMERICA
The pipeline of new anti-cancer agents - most of which are considered “molecularly 
targeted drugs”- has markedly expanded in the last few years. This pipeline is 
particularly relevant to advanced NSCLC where molecular phenotyping as a component 
of clinical decision-making is rapidly becoming entrenched as standard-of-care. Many 
of these agents are in early phase clinical testing, with the most promising compounds 
immediately being deployed by sponsors into the Phase III context as a registration 
strategy. However, the resource demands of a phase III clinical trial (which can 
exceed $100 million in costs) require a re-evaluation of the preceding phase II efficacy 
screening program. It is a common observation in NSCLC drug development that 
many “encouraging” or “positive” phase II trials fail to subsequently translate into a 
positive phase III trial. For example, in the past two decades several phase III trials in 
the NSCLC frontline setting have failed, despite promising initial phase II results. These 
trials were largely conducted in patient populations in which there was no selection 
of patients most likely to benefit based on tumor biology. Many of these trials were 
designed to test the efficacy of a novel agent to platinum-based doublet therapy (vs. a 
platinum doublet alone). Unfortunately, the vast majority of these trials failed to show 
a significant improvement in survival in the experimental arm. In fact, only two trials 
showed improvement in overall survival for the addition of a new agent to platinum-
based therapy: E4599 (bevacizumab + carboplatin/paclitaxel) and FLEX (cetuximab 
+ cisplatin/vinorelbine). Thus, it is apparent that there is a “disconnect” between the 
results of phase II and phase III results in advanced NSCLC. It is therefore imperative 
to address the usual issues in phase II drug development to help improve the chances 
of a subsequently positive phase III trial. Among those issues are 1) the availability of 
a novel active agent with a sufficient safety profile in phase I; 2) appropriate patient (or 
molecular) selection; and 3) an appropriate study design and endpoints. As noted above, 
there is currently a plethora of potentially active agents in NSCLC, many of which can 
be directed towards “druggable” driver oncogenic alterations such as EGFR, KRAS, or 
ALK, or towards critical signaling molecules that may be involved in bypass pathway 
activation or drug resistance such as MET, AKT, or MEK. These agents are now rapidly 
being screened in the phase I and II settings – many in molecularly defined patient 
subsets - for potential translation into the phase III context. Examples of these agents 
and their biologic targets (as a component of patient selection), and how best to prioritize 
their development in the era of limited resources, will be highlighted in the presentation. 
Finally, the selection of the appropriate phase II primary endpoint as an efficacy screen 
cannot be over-emphasized. Historically, tumor response rate (CR + PR) - measured 
using the Response Evaluation Criteria in Solid Tumors (RECIST) - had been used as 
a phase II endpoint because of a presumption that this was associated with subsequent 
survival or palliative benefit. Disease Control Rate (DCR), the sum of complete and 
partial response and stable disease rates (CR+PR+SD), was later shown to be a more 
powerful predictor of subsequent survival than the traditional response rate (CR + PR) 
in patients receiving platinum-based chemotherapy for advanced stage NSCLC. More 
recently, phase II trials have started adopting time- or progression-related endpoints 
such as Progression-Free Survival (PFS) or Time-to-Progression (TTP). Investigators 
should be aware not only of the potential advantages of these composite endpoints, 
but of the potential pitfalls as well (which will be discussed during the presentation). 
In conclusion, there are many more new agents directed against NSCLC that are ready 
for phase II efficacy screening as are available resources, compelling investigators to 
ensure that the phase II process is well-prioritized and the trials appropriately designed. 
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INTENSITY MODULATED RADIOTHERAPY OR PROTON BEAM 
THERAPY FOR LOCALLY ADVANCED NSCLC
Ritsuko Komaki  
UT MD Anderson Cancer Center, Houston/UNITED STATES OF AMERICA
Intensity Modulated Radiation Therapy (IMRT) or Proton Beam Therapy (PBT) for 
Locally Advanced NSCLC Ritsuko Komaki, MD, FACR, FASTRO Professor of Radiation 
Oncology Gloria Lupton Tennison Distinguished Endowed Professor for Lung Cancer 
Research Departments of Radiation Oncology, University of Texas MD Anderson Cancer 
Center Background: The standard of care for patients with locally advanced non-
small cell lung cancer with good performance status is concurrent chemotherapy and 
radiation therapy (RT). The superiority of this approach was demonstrated in a series of 
randomized trials in the era of 2-dimensional (2D) RT. However, patients treated with 
concurrent RT and chemotherapy are at risk of toxic effects such as severe esophagitis, 
pneumonitis, and bone marrow toxicity that can lead to delayed or missed treatments or 
hospitalizations, resulting in both lesser treatment efficacy and greater medical costs. We 
showed that using 3D conformal (X-ray) RT (CRT) can cut the risk of severe esophagitis 
in half relative to 2D RT. We also showed that use of intensity-modulated (X-ray) RT 
(X-IMRT) can further reduce the risk of treatment-related pneumonitis, but not that 
of esophagitis, relative to 3D CRT. Hypothesizing that the physical dose characteristics 
of protons will allow proton beam therapy (PBT) to spare critical structures such as 
esophagus, lung, and bone marrow from incidental irradiation to a greater extent than 
X-ray therapy, we evaluated the rates of severe esophagitis, pneumonitis, and bone 
marrow suppression in patients with locally advanced NSCLC treated with concurrent 
chemotherapy with either PBT or X-IMRT. Methods: From January 2003 to June 2008, 
128 patients with locally advanced NSCLC were treated with chemotherapy+PBT (62 
patients) or chemotherapy+X-IMRT (66 patients); all had concurrent chemotherapy, 
none had had prior thoracic RT, and all were treated to at least 60 Gy (for X-IMRT) or 60 
CGE (cobalt-60Gy-equivalent) (for protons). Patients who had both IMRT and 3D CRT or 
PBT were excluded. Toxicity was graded according to the Common Terminology Criteria 
for Adverse Events version 3.0. Results: The median follow-up times for the PBT group 
and the X-IMRT group patients were 15.2 months (range, 3.1–25.7 months) and 17.4 
months (range, 1.4–37.6 months), respectively. Median patient age was 67 years (PBT) 
and 62 years (X-IMRT) (P<0.04). Karnofsky performance scores for both groups were 80. 
Nodal involvement was slightly more common in the X-IMRT group (91%) than in the 
PBT group (81%) (P>0.05). Median dose was 74 CGE (range, 63-80.5 CGE) for the PBT 
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group vs. 63 Gy (range, 60-76 Gy) for the X-IMRT group (P<0.001). Patients treated with 
PBT experienced significantly smaller reductions in hemoglobin (P<0.001), neutrophils 
(P<0.008), lymphocytes (P<0.001), and white blood cells (P <0.001) compared with those 
treated with X-IMRT. No significant differences were found between groups in platelet 
counts. Severe (grade 3+) esophagitis occurred in 44% of patients treated with X-IMRT 
vs. 5% with PBT. Severe (grade 3+) treatment-related pneumonitis was observed in 9% 
of the X-IMRT group vs. 2% of the PBT group. Conclusions: Our preliminary analysis 
of patients with locally advanced NSCLC suggests that treatment with concurrent 
chemotherapy+PBT leads to less bone marrow toxicity than does treatment with 
concurrent chemotherapy+X-IMRT, which could allow the use of more aggressive 
systemic regimens for such patients. This supposition needs to be tested prospectively 
in a randomized trial. The considerable reduction in esophageal reactions after PBT is 
consistent with the predicted sparing of normal tissues. The ongoing reductions in severe 
treatment-related pneumonitis (from 32% after 3D CRT to 9% after X-IMRT to 2% after 
PBT) are consistent with the ability of advanced technologies to spare normal lung. 
These findings have led to the development of a prospective randomized comparative 
trial of PBT vs. X-IMRT (funded by the U.S. National Cancer Institute) conducted 
jointly at MD Anderson and Massachusetts General Hospital. Both arms of the study 
will involve high-dose radiation (66 Gy to 74 Gy) with concurrent carboplatin and 
paclitaxel chemotherapy. The endpoints are local tumor control and severe treatment-
related pneumonitis. Tumor motion is being accounted for by using 4D CT simulation 
to develop internal target volumes for use with breath-hold or gating techniques. Future 
developments in PBT such as discrete spot scanning and intensity-modulated proton 
therapy must await resolution of tumor motion issues when these advanced techniques 
are to be used for proton delivery. 
Keyword: IMRT vs. PBT for Locally Advanced NSCLC
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ACHIEVEMENTS AND CHALLENGES OF SABR IN NON-SMALL 
CELL LUNG CANCER
Luhua Wang, Jingbo Wang, Nan Bi  
Department Of Radiation Oncology, Chinese Academy Of Medical Science & Peking 
Union Medical College, Beijing/CHINA
Stereotactic ablative radiotherapy (SABR) has been increasingly used in early-stage 
(mainly T1-2N0M0) of non-small cell lung cancer (NSCLC) in under two decades. 
With the promising results of SABR, more needs are emerging to obtain a better 
understanding in terms of the achievements and challenges of this technique to optimize 
its utility in NSCLC. Conventionally, SABR is considered the stand care for inoperable, 
peripherally located and stage T1-2N0 NSCLC. For patients with past history of 
thoracic surgery or radiation therapy, or those with sever pulmonary disease leading to 
intolerance to surgery, SABR is also regarded as the preferred option. SABR provided 
an extremely high 3-y local control rate for this subgroup of patients (90%-98%) and 
the 3-y overall survival (OS) of 56%-90%. The SABR related toxicity was mild and no 
clinically relevant deteriorations in quality of life subscale scores were observed after 
SABR. Given the encouraging outcomes of SABR in early reports, radiation oncologists 
are trying to extend this technique to operable and central NSCLC. An US retrospective 
study comparing the SABR with wedge-resection in stage I NSCLC, with patients 
in SABR group elder than those treated with surgery, showed that SABR provided 
favorable local, regional tumor control and similar cancer-specific survival. Based on 
a multi-institutional database, a Japanese study retrospectively reviewed the treatment 
outcome of SABR in medically operable patients with stage I NSCLC, demonstrating 
the cumulative 5-y local control rates of 92% and 73% for stage T1 and T2 diseases, 
corresponding to the 5-y OS of 72% and 62%, respectively. Netherland reported a 3-y 
OS of 84.7% and local control rate of 93% for potentially operable patients with stage I 
NSCLC. A phase II study, JCOG 0403, reported a 76% of 3-y OS and 86% of 3-y LC rate 
with a median age of 79, which were comparable to the surgery-based outcome reported 
previously. However, stronger data from randomized study (such as RTOG 0618, 
POSTILV) are pending. 
As for the administration of SABR in centrally located NSCLC, a couple of retrospective 
and small cohort study showed that SABR provided excellent local control for central 
tumors with less aggressive dose fractionation. However, the applied dose fractionations 
among studies were inconsistent and reported occurrences of toxicity were with great 
heterogeneity as well. The ongoing RTOG 0813 is to determine the maximal tolerated 
dose (MTD) of SBRT for centrally-located NSCLC and the corresponding control rate 
at the MTD of SBRT for the specific population. However, one needs to be aware of the 
challenges of the administration of the extending application of SABR. So far, surgical 
resection is still the standard care for operable early-stage of NSCLC. Besides the 
elimination of primary tumor, surgery allows for lymph nodes dissection or sampling 
to identify the accurate N status. On the other hand, the surgery can provide sufficient 
tissue sample for genotyping to guide individualized therapy. Moreover, the introduction 
of video-assistant thoracic surgery (VATS) brought significant technique advance to 
thoracic surgery, in particular for patients with peripheral and small lesion of diseases. 
The advantages of this minimally invasive approach over traditional thoracotomy 
include diminished duration and intensity of pain, a shorter time to return to full 
activity, minimal risk of intraoperative bleeding and the low postoperative morbidity 
and mortality. The long-term survival and local control rate for stage I NSCLC from 
VATS were comparable to that achieved by routine thoracotomy resection. SABR is a 
highly conformal radiation technique. Safe and effective delivery of SABR to tumor 
lesions is facilitated by the minimum setup margin, small internal margin and beams 
convergence calls for the precise quality control system including image-guided 
equipment (IGRT), minimizing or tracking respiratory motion and non-coplanar 3-D 
multiple beams to deliver high dose of irradiation to focal sites within a short period. 
Accurate staging, especially N staging is essential for the administration of SABR. 
Minimally invasive procedures, such as mediastinoscopy are still considered the 
standard approaches for N staging. EBUS-TBNA and EUS-FNA are alternative options 
for invasive N staging. PET/CT significantly improves the accuracy in staging of NSCLC, 
especially for N and M staging. The false negative risk of nodal metastasis for PET/CT 
determined stage I NSCLC was reported to be less than 15% and the occult mediastinal 
metastasis was less than 10%, which may be even lower for those with peripheral 
diseases. Even though, how much confidence do we have in SABR candidate selection? Is 
the incidental irradiation is enough to control the regional failure? 
With the prolonged follow up time, the studies regarding pattern of failure after 
SABR are available. The findings from different studies consistently reported that the 
recurrences were uncommon. The most often recurrence events were isolated distant 
recurrences, which would probably not be affected by the local treatment used. There 
were only one third of recurrences were loco-regional. These findings provide more 
confidence to clinicians as technological advances have led to a greater access to SABR 
worldwide. In addition, most recurrences and second primary events occurred in the 
first 3 years after SABR, the investigators recommended that 6-monthly assessments 
during this period might represent an efficient follow-up schedule. Undoubtedly, 
SABR has created great achievement in inoperable stage I NSCLC. However, plenty of 
challenges are to be resolved to increase the application of SABR to a more extensive 
population. 
Keyword: SABR, Non-small cell lung cancer
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EML4-ALK AND OTHER FUSION KINASES IN LUNG CANCER
Hiroyuki Mano  
Department Of Medical Genomics, The University Of Tokyo, Tokyo/JAPAN
To identify essential growth drivers in lung cancer, we developed a highly sensitive 
functional screening system with retroviral cDNA expression libraries. Application 
of this technology to a non-small cell lung cancer (NSCLC) specimen identified the 
EML4-ALK fusion oncogene (Nature 448:561). Wild-type EML4 and ALK genes encode a 
structural protein and a receptor-type protein-tyrosine kinase, respectively, but a small 
inversion within the short arm of chromosome 2 leads to production of a fusion protein 
between an N-terminal half of EML4 and the intracellular kinase domain of ALK. 
Transgenic mice expressing EML4-ALK generate hundreds of lung adenocarcinoma 
nodules soon after birth, but such nodules are rapidly cleared in response to a treatment 
with ALK inhibitors, suggesting that EML4-ALK-positive tumors are profoundly 
addicted to its elevated enzymatic activity (PNAS 105:19893). EML4-ALK is present in 
~4% of NSCLC, and highly enriched in lung adenocarcinoma with young onset and in 
never- or light-smokers (Clin Cancer Res 14:6618). In response to such observation, a 
large number of ALK inhibitors are currently under development or clinical trials, and 
a marked efficacy of the first inhibitor (crizotinib) was already reported with a disease 
control rate of ~80% (NEJM 363:1693). Only 4 years after our initial discovery of EML4-
ALK, crizotinib was approved, as of August 26, 2011, as a therapeutic drug against lung 
cancer by U.S. FDA, which was the record-breaking speed in the history of cancer drug 
development. Crizotinib is also available in other countries as well, including Japan, 
Canada, and Korea. Currently a total of six independent ALK inhibitors and one Hsp90 
inhibitor are under clinical trials for the treatment of EML4-ALK-positive NSCLC. 
Progression free survival for ALK-positive individuals with crizotinib treatment is ~1 
year (Lancet Oncol 12:1004), indicating that tumors eventually acquire resistance against 
some ALK inhibitors. From a patient with NSCLC who was once effectively treated 
with crizotinib but underwent rapid relapse after 6 months’ treatment, we discovered 
secondary mutations within EML4-ALK that confer resistance to ALK inhibitors (NEJM 
363:1734). One of the acquired mutations was L1196M substitution, and, interestingly, 
Leu-1196 of ALK is placed at the identical position in its three-dimensional structure to 
Thr-790 in EGFR and Thr-315 in ABL which are also the positions for resistant mutations 
against gefitinib and imatinib, respectively. This “gatekeeper” position is placed at the 
bottom of the ATP-binding pocket. Therefore, substitution of the side chain at this 
amino acid residue should significantly affect the affinity of tyrosine kinase inhibitors 
(TKIs) to each ATP-binding pocket. After our report of crizotinib-resistant mutations, 
a number of missense mutations were shown to be responsible for such resistance, but, 
as expected, L1196M is the most frequent one to confer drug resistance. While it is quite 
difficult to raise effective TKIs against EGFR(T790M) or BCR-ABL(T315I), there are 
already several TKIs that can suppress the growth of EML4-ALK(L1196M)-positive 
tumors, and some of them had undergone clinical trials. In addition to EML4-ALK, 
we further identified distinct rare fusions of ALK, i.e., KIF5B-ALK (Clin Cancer Res 
15:3143) and KLC1-ALK (PLoS ONE 7:e31323), which should be similarly treated with 
ALK inhibitors. Interestingly, we and others independently discovered that 1~2% of 
lung adenocarcinoma carry RET fusion kinases (KIF5B-RET and CCDC6-RET) (Nat 
Med 18:378, Nat Med 18:375, Nat Med 18:382). Since such RET fusions possess elevated 
tyrosine kinase activities, NSCLC positive for RET fusions should be effectively treated 
with RET-specific inhibitors as in the case for EML4-ALK and ALK inhibitors. Further, 
we and others isolated various ROS1 fusions (TPM3-ROS1, SDC4-ROS1, etc.) in 1~2% 
of lung adenocarcinoma (Nat Med 18:378, Cell 131:1190). Fortunately, crizotinib has an 
IC50 of nano molar range against ROS1 tyrosine kinase, and treatment with this drug 
indeed benefited markedly a patient with lung adenocarcinoma positive for ROS1 fusion 
(JCO 30:863). Summing up, this series of scientific discovery and very rapid application 
of such findings to the clinics is a proof-of-concept for the hypothesis that “targeting 
essential growth driver would become a magic drug for cancer treatment.” Furthermore, 
ALK may become fused to partners not only in NSCLC, but in other malignancies 
as well, such as NPM1-ALK in lymphoma, VCL-ALK in renal medullary carcinoma, 
and TPM3/TPM4-ALK in inflammatory myofibroblastic tumor. I propose such ALK-
dependent tumors be collectively termed as “ALKoma”, which should be an early, but 
very good example for gene-based “beyond organ” re-classification of human cancer 
(Cancer Discov 2:495).
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IRREVERSIBLE EGFR-TKI
James C. Yang  
Graduate Institute Of Oncology And Cancer Research Center, National Taiwan 
University College Of Medicine, /TAIWAN
The role of gefitinib and erlotinib for the treatment of EGFR mutation positive patients 
were established in many randomized studies. Most if not all patients develop resistance 
to gefitinib or erlotinib with a median of 10 to 13 months. There is a high unmet need for 
the treatment of gefitinib or erlotinib resistant patients. Second generation EGFR TKIs 
such as afatinib or dacomitinib are irreversible EGFR inhibitors. They have the potential 
to inhibit the proliferation of resistant exon 20 T790M mutation in the EGFR mutation 
positive tumor cells. Afatinib was tested in 129 EGFR mutation positive patients. The PFS 
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of patients with del 19 and L858R were 13.7 months with independent review. Afatinib 
was compared with pemetrexed and cisplatin as first line treatment in EGFR mutation 
positive lung adenocarcinoma patients. The long PFS (13.6 months) was confirmed in 
patients with one of the common EGFR mutations. Overall, afatinib was superior to 
pemetrexed and cisplatin in 345 randomized patients in PFS (11.1 month vs. 6.9 months, 
H.R. 0.58, P=0.0004), response rates by independent review and patient reported 
outcome. Dacomitinib was evaluated in phase II studies. In patients with common 
EGFR mutations, the PFS was 16.4 months and 18.3 months for patients with EGFR 
del 19 and exon 21 mutation respectively. In a randomized phase II study, dacomitinib 
was compared to erlotinib in NSCLC patients. The PFS was 12.4 weeks vs. 8.3 weeks, 
H.R. 0.66, P=0.012). A phase III study of similar design (ARCHER) is being conducted. 
Salvage treatment after gefitinib or erlotinib failure has become an important issue 
recently when EGFR-TKI became a standard treatment for these patients. Afatinib was 
studied in patients who failed one or two lines of EGFR-TKI and erlotinib or gefitinib 
after at least 3 months of use. In that phase IIB/III international study, patients were 
randomized to afatinib or placebo. The overall survival endpoint was not met but there 
was a big difference in PFS (3.3 months for afatinib vs. 1.1 months for placebo). Afatinib 
and Cetuximab combination, on the contrary, were even more effective in the same 
population. Future phase III study is warranted. Irreversible EGFR-TKI has become one 
of the armamentarium for us to fight with EGFR mutation lung cancer. 
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TREATMENT OF LOCALLY ADVANCED SCLC
Kaoru Kubota  
Thoracic Oncology, National Cancer Center Hospital, Tokyo/JAPAN
Small-cell lung cancer (SCLC) accounts for about 10-15% of all lung cancer. Although 
the incidence of SCLC has been declining, estimated mortality of this disease is similar 
to ovarian cancer, leukemia, and non-Hodgkin lymphoma. Rapid tumor growth of 
SCLC contrasts with the slow pace of SCLC investigation. SCLC has often been staged 
as limited or extensive disease. Limited SCLC (LD-SCLC) is defined as tumor confined 
to one hemithorax and the regional lymph nodes, whereas extensive (ED-SCLC) is 
defined as disease beyond these bounds. Systemic combination chemotherapy is the 
cornerstone of treatment both in LD- and ED-SCLC. Two meta-analyses published in 
1992 revealed that the addition of thoracic radiotherapy to chemotherapy significantly 
improved overall survival compared to chemotherapy alone in patients with LD-SCLC1, 
2). Although cisplatin plus etoposide (PE) and early concurrent thoracic radiotherapy 
resulted in the best outcome3, 4), conflicting results have been reported regarding the 
timing of thoracic radiotherapy. To investigate whether thoracic radiotherapy combined 
with the third cycle of PE is non-inferior to thoracic radiotherapy combined with the 
first cycle of PE, Park and colleagues conducted a randomized trial comparing the first 
cycle to the third cycle of concurrent chemoradiotherapy5). They employed cisplatin 
70mg/m2 on day 1 and etoposide 100mg/m2 on days 1 to 3 as PE, and 2.1Gy once-daily 
in 25 fraction over five weeks with a total dose of 52.5Gy as thoracic radiotherapy. 
Between July 2003 and June 2010, 219 patients were enrolled. The median overall 
survivals were 24.1 and 26.8 months (P=0.60) in the first and third cycle combination, 
respectively. Median progression-free survival and 5 year overall survival were 12.2 vs. 
12.1 months and 24.3% vs. 24.0% in the first and third cycle combination, respectively. 
More febrile neutropenia was observed in the first cycle combination. They concluded 
that thoracic radiotherapy beginning with the third cycle of chemotherapy showed 
comparable survival outcomes with thoracic radiotherapy beginning with the first cycle 
of chemotherapy with a lower frequency of febrile neutropenia. Turrisi and colleagues 
reported that twice-daily thoracic radiotherapy (accelerated hyperfractionated thoracic 
radiotherapy: AHTRT) beginning with the first cycle of chemotherapy significantly 
improved survival as compared with concurrent once-daily radiotherapy (P=0.04 by 
the log-rank test). Thus the first cycle of PE combined with AHTRT is the standard 
treatment for LD-SCLC. Because irinotecan plus cisplatin (IP) significantly improved 
overall survival compared to PE for ED-SCLC, Japan Clinical Oncology Group (JCOG) 
conducted a randomized trial comparing PE with IP following one cycle of EP plus 
AHTRT for LD-SCLC. From Sep 2002 to Sep 2006, 281 patients were registered. After 
the induction chemoradiotherapy, 258 patients were randomized to consolidation PE 
or IP. The median overall survivals and 5-year survivals were 3.2 vs. 2.8 years and 36% 
and 34% in the PE and IP group, respectively. PE plus AHTRT followed by 3 cycles of IP 
failed to demonstrate survival advantage over 4 cycles of PE plus AHTRT, which is still 
the standard treatment for LD-SCLC. Four cycles of PE plus AHTRT resulted in overall 
five-year survival of 36 percent, a considerable improvement in survival over previous 
results in patients with LD-SCLC. 
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BIOLOGICAL CHARACTERISTICS & THERAPEUTIC  
MOLECULAR TARGETS OF SCLC
Jiichiro Sasaki 
Department of Respiratory Medicine, Kitasato University School of Medicine/JAPAN
Unfortunately, we had no progress of therapeutic procedures and strategies against 
extensive stage small cell lung cancer (SCLC) in this decade. SCLCs are totally different 
from non-small cell lung cancers (NSCLCs) not only clinically but also biologically. 
SCLC cells can make a spheroid formation even in the adherent culture condition in 
vitro and have unique profiles of membrane protein to compare with those of NSCLC 
cells. Since serial discoveries of oncogene driver mutations and alterations in NSCLC, 
several explorative genomic analyses have been performed to seek new therapeutic 
molecular targets in SCLC. Inactivation of TP53 and RB1 has been frequently found 
in SCLC cells. Mutation of c-MET and amplification of FGFR1 has been also reported. 
Recent integrative genome analysis revealed that SCLC had an extremely high mutation 
rate due to mutations in the genes associated with histone modification. Now, we can 
find any genomic alterations using recent molecular technique with high quality, but  
we need an exact methodology to select and define a dominant mutation associated  
with carcinogenesis or tumor progression in SCLC. 
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CHEMOTHERAPY WITH TARGET AGENTS IN ADVANCED NON-
SMALL CELL LUNG CANCER
Caicun Zhou  
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School Of Medicine, Shanghai/CHINA
Lung cancer is the leading cause of cancer related death in the world. Platinum-based 
chemotherapy used to be a standard first-line therapy for advanced non-small cell lung 
cancer (NSCLC) but its efficacy is modest compared with best supportive care. In the 
past several years some targeted agents have been approved in the treatment of advanced 
(NSCLC). Combination of the targeted agents and chemotherapy has widely been 
studied in order to improve outcome of NSCLC. 
 
1. Chemotherapy with anti-EGFR agents Two methods have been developed to inhibit 
EGFR signaling pathways, monoclonal antibodies against extracellular domain of 
EGFR and small molecular inhibitors of tyrosine kinase of EGFR (EGFR TKI). EGFR 
TKI monotherapy is a standard 1st line therapy for advanced NSCLC patients with 
positive EGFR mutations. It is associated with better progression free survival (PFS), 
tumor response rate, safety profile and quality of life, compared with chemotherapy. 
Addition of chemotherapy into EGFR TKI could not further improve efficacy of 
EGFR TKI in advanced EGFR-mutant NSCLC. In CALGB 30406 trial, PFS, overall 
survival (OS) and tumor response rate were comparable between those on erlotinib 
alone and those on erlotinib plus standard chemotherapy. Four randomized phase III 
trials compared standard chemotherapy alone with chemotherapy plus EGFR TKI in 
unselected advanced NSCLC. They all failed to show any benefit with the addition of 
EGFR TKI. But, the combination of chemotherapy and EGFR TKI may be effective 
when EGFR TKI fails. A retrospective study compared efficacy of continuation of 
erlotinib and chemotherapy with chemotherapy alone in 78 patients who developed 
disease progression to EGFR TKI. Partial responses occurred in 41% of the patients 
in combination subset compared to 18% with chemotherapy alone (p=0.02). But PFS 
and OS were not statistically different. Intercalated combination of EGFR TKI and 
chemotherapy may work. FAST-ACT (I and II) studies showed the improvement in 
tumor response and PFS with integrating EGFR TKI (d14-d28) and chemotherapy 
(d1, d8), compared with chemotherapy plus placebo. A similar intercalated regimen 
combining paclitaxel/carboplatin (d1) with erlotinib (d2 to d15) was reported. Only 
patients with positive EGFR mutations demonstrated a higher 6 month PFS rate with 
erlotinib compared with those without. Intermittent combination of docetaxel (d1) 
and erlotinib (d2-d6) showed encouraging efficacy in terms of tumor response rate 
(35%) and PFS (5.8 months) in a phase II trial of previously treated NSCLC patients. 
In maintenance setting, PFS was significantly improved with gefitinib or erlotinib and 
OS with erlotinib. Several studies have investigated combination of cetuximab and 
standard chemotherapy in 1st line treatment of advanced NSCLC. Only In FLEX study, 
a improvement in OS was observed with cetuximab compared with placebo. But PFS 
was the same on the both arm. A new biomarker using the H-score of EGFR may help to 
select patients. The patients with H-score of 200 or more could get higher tumor response 
rate, PFS and OS with cetuximab and chemotherapy compared with chemotherapy 
alone. Dr. Kim compared pemetrexed plus cetuximab with pemetrexed plus placebo in 
second line treatment of non-squamous NSCLC (SELECT trial). No improvement in 
efficacy was observed with cetuximab, even in those with positive EGFR expression. 
 
2. Combination of chemotherapy and bevacizumab ECOG 4599 and AVAiL studies 
compared efficacy of bevacizumab plus standard chemotherapy with placebo plus 
standard chemotherapy in the 1st line treatment of non-squamous NSCLC. Tumor 
response rate and PFS were significantly improved with bevacizumab compared with 
placebo. OS was improved with bevacizumab in ECOG 4599 trial. Subgroup analysis 
showed that the patients with adenocarcinoma survived the longest with median OS 
of 14.2 months. The findings of the two studies were further confirmed by two large 
phase IV studies, SAiL and Aries. Two phase II studies investigated combination of 
bevacizumab and pemetrexed/platinum in the 1st line treatment of non-squamous 
NSCLC. The combination is feasible and effective, with PFS of 7.8months. AVAPERL 
is a randomized phase III study comparing bevacizumab plus carboplatin/pemetrexed 
followed by maintenance of bevacizumab with bavacizumab plus pemetrexed up to 
disease progression. Bevacizumab plus pemetrexed in maintenance setting succeeded 
in prolonging PFS (from induction phase, 10.2 months vs 6.6 months, HR 0.50, 95% CI 
0.37-0.69, p<0.001 and from maintenance phase, 7.4 months vs 3.7 months, HR 0.48, 
95% CI 0.35-0.66, p<0.001). No signals of novel adverse events or unexpected toxicity 
were observed in the combination arm. ABIGAIL study indicated that patients with 
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lower plasma VEGF A level at baseline was associated with a longer PFS (low vs high, 7.4 
months vs 6.1 months, HR 1.57, 95% CI 1.17-2.09, p=0.002). 
 
3. Combination of chemotherapy and small molecular multi-target agents Many 
phase III studies were dedicated to investigate the efficacy and safety of small molecular 
multi-target agents in advance NSCLC, including BIBF 1120, sorafenib, sunitinib, 
cediranib, linifanib, etc. All of them failed to demonstrate better efficacy with these 
agents compared with chemotherapy alone but increased toxicity, especially in those 
with squamous carcinoma.  
 
In conclusion, EGFR TKI monotherapy is a standard 1st line therapy for advanced 
NSCLC with EGFR mutations. Addition of chemotherapy could not further improve 
efficacy of EGFR TKI. Intermittent combination of EGFR TKI and chemotherapy may 
be effective but needs to be validated. Chemotherapy plus bevacizumab is a standard 
1st line for non-squamous NSCLC, especially for adenocarcinoma. Combination of 
bevacizumab and pemetrexed in the maintenance setting could further improve clinical 
benefit. In the new era of individualized treatment, more efforts need to be taken in order 
to find a predictive biomarker for selection of patients on bevacizumab. 
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CHEMOTHERAPY WITH CYTOTOXIC DRUG
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Pemetrexed (PEM) is one of key cytotoxic drug for non-squamous non-small cell lung 
cancer. Cisplatin plus pemetrexed demonstrated superior survival benefit than cisplatin 
plus gemcitabine for non-squamous non-small cell lung cancer subset in JMDB trial. 
Overall survival was statistically superior for cisplatin plus pemetrexed versus cisplatin 
plus gemcitabine in patients with adenocarcinoma (12.6 versus 10.9 months, HR=0.84, 
p=0.03) and large-cell carcinoma histology (10.4 versus 6.7 months, HR=0.67, p=0.03). 
Non other platinum-based doublets demonstrated statistically significant survival 
benefit when compared with platinum and third-generation drugs. More over both 
switch and continuation maintenance of pemetrexed prolonged not only progression-
free survival but also overall survival of non-squamous non-small cell lung cancer 
patients. Switch maintenance of pemetrexed after four cycles of platinum-based 
chemotherapy significantly improved progression-free survival (4.3 versus 2.6 months, 
HR=0.50, p<0.0001) and overall survival (13.4 versus 10.6 months, HR=0.79, p=0.012) 
compared with placebo in JMEN trial. Quality of life during maintenance therapy 
with pemetrexed is similar to placebo, except for a small increase in loss of appetite, 
and signifi cantly delayed worsening of pain and haemoptysis. In PARAMOUNT trial, 
continuation maintenance of pemetrexed after four cycles of cisplatin plus pemetrexed 
significantly improved progression-free survival (4.1 versus 2.8 months, HR=0.62, 
p<0.0001) and overall survival from randomization (13.9 versus 11.0 months, HR=0.78, 
p=0.012) compared with placebo. Recently, many molecular target drugs for various 
type of neoplasma are under the development in the world. In contrast, only few new 
cytotoxic drugs for non-small cell lung cancer were developing in the recent decade. 
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is 130-nm albumin-bound and 
Cremophor EL–free formulation of paclitaxel (Abraxane) designed to avoid solvent-
related toxicities. nab-paclitaxel plus carboplatin demonstrated a significantly higher 
overall response rate than paclitaxel plus carboplatin (33% versus 25%, p=0.005) and 
in patients with squamous histology (41% versus 24%, p <0.001). The progression-free 
survival (median, 6.3 versus 5.8 months, HR=0.902, p=0.214) and overall survival 
(median, 12.1 v 11.2 months, HR=0.922, p=0.271) in the nab-paclitaxel plus carboplatin 
arm were approximately 10% improved than the paclitaxel plus carboplatin arm but they 
did not achieve statistical difference. Eribulin mesylate is a halichondrin B analogue 
that acts as a nontaxane microtubule dynamics inhibitor. Eribulin was approved in the 
United States in 2010 for the treatment of metastatic breast cancer. In non–small cell 
lung cancer, median overall survival in eribulin-treated patients has been reported as 
9.4 months in an unselected population and varies according to taxane sensitivity: 12.6 
months in taxane-sensitive disease versus 8.9 months in taxane-resistant disease. The 
randomized phase III study of eribulin previously treated non-small cell lung cancer is 
now on-going. 
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In the 2011 IASLC/ATS/ERS lung adenocarcinoma (ADC) classification major changes 
are recommended for adenocarcinomas diagnosed in resection specimens:1 1) the term 
bronchioloalveolar carcinoma (BAC) should not be used anymore, because tumors 
previously classified under as BAC are represented by five different tumors in this 
classification; 2), for solitary tumors measuring ≤3cm, new concepts of adenocarcinoma 
in situ (AIS) and minimally invasive adenocarcinoma (MIA) have been introduced for 
lesions that have no invasion or ≤5mm invasion, respectively; these patients should 
have 100% or near 100% disease free survival (DFS); 3) for invasive adenocarcinomas, 
comprehensive histologic subtyping of each histologic subtype present in 5% increments 
is recommended for evaluation with classification according to the predominant 
subtype; 4) micropapillary adenocarcinoma is proposed as a new subtype with a poor 
prognosis; 5) the term lepidic replaces BAC for tumors with a predominant component 
formerly called non-mucinous BAC, and the term lepidic predominant adenocarcinoma 
is recommended along with discontinuing the term “mixed subtype”; 6) invasive 
mucinous adenocarcinoma (IMA) is the term used to replace those formerly classified 
as mucinous BAC. Invasive ADC represents complex mixtures of a spectrum of 
histologic patterns. Historically this presented an obstacle to pathologists in sorting 
out biologically meaningful subsets of overtly invasive adenocarcinomas that could 
be used for correlations with prognosis and molecular findings. A growing number of 
studies from around the world have shown significant survival correlations in early 
stage adenocarcinomas according to the classification.2-6 All studies have shown 100% 
5-year DFS for AIS and MIA (100%).2-6 Favorable prognosis (≥90% 5 yr DFS) has been 
seen for lepidic predominant ADC. Most studies have shown intermediate survival for 
acinar and papillary predominant ADC as well as poor prognosis for micropapillary and 
solid predominant tumors. 2-6 Survival for invasive mucinous adenocarcinoma has been 
more variable.3;5;6 The most robust molecular histologic correlation is with IMA most 
of which show KRAS mutations.7EGFR mutations are seen with all histologic subtypes, 
but are reported most often with lepidic and papillary predominant ADC. There is 
no established grading system for lung ADC. However, this classification effort has 
stimulated several investigations into this topic. The architectural patterns defined in the 
ADC classification easily translate into grading categories with prognostic significance. 
According to this concept AIS, MIA and lepidic predominant ADC are low grade with 
intermediate grade acinar and papillary ADC and high grade solid and micropapillary 
ADC. This has been shown in several studies according with grading according to the 
single most predominant pattern.3;5;6 Another approach used the two most predominant 
patterns to present a histologic grading system with prognostic significance.8 Based 
upon a detailed evaluation of multiple nuclear features in Stage I lung ADC, a grading 
system was recently proposed using a combination of architectural features and mitotic 
count.2 Nakazato Y et al showed that nuclear area and nuclear size are independent 
prognostic markers.9 As proposed in the IASLC/ATS/ERS classification, both pathologic 
and CT data have suggested that tumor size may best be predicted according to the size 
of the solid component rather than total tumor size.2;3;6;10 The concepts proposed in this 
classification are a major change for practicing pathologists. One of the questions has 
concerned reproducibility and three studies have been published on this subject.11-13 
One showed recognition of predominant pattern was 0.77 and 0.38 in typical and 
difficult cases, respectively. Agreement was the highest for the solid pattern and the 
least for micropapillary pattern.11 Two additional studies showed that training increases 
concordance among pathologists in classifying pulmonary ADC according to the 
2011 classification.12;13 These studies demonstrate the need for expert and practicing 
pathologists to work together to develop better consensus on how to interpret these 
patterns and that these efforts may prove fruitful. Reference List (1) Travis WD, et 
al. The New IASLC/ATS/ERS International Multidisciplinary Lung Adenocarcinoma 
Classification. J Thoracic Oncol 2011;6:244-85. (2) Kadota K, et al. A grading system 
combining architectural features and mitotic count predicts recurrence in stage I lung 
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Adenocarcinomas with prominent lepidic spread: retrospective review applying new 
classification of the American Thoracic Society. Am J Surg Pathol 2012;36:273-82. 
(5) Russell PA, et al. Does lung adenocarcinoma subtype predict patient survival?: A 
clinicopathologic study based on the new International Association for the Study of 
Lung Cancer/American Thoracic Society/European Respiratory Society international 
multidisciplinary lung adenocarcinoma classification. J Thorac Oncol 2011;6:1496-
504. (6) Yoshizawa A, et al. Impact of proposed IASLC/ATS/ERS classification of lung 
adenocarcinoma: prognostic subgroups and implications for further revision of staging 
based on analysis of 514 stage I cases. Mod Pathol 2011;24:653-64. (7) Sica G, et al. A 
grading system of lung adenocarcinomas based on histologic pattern is predictive of 
disease recurrence in stage I tumors. Am J Surg Pathol 2010;34:1155-62. (8) Nakazato 
Y, et al. Nuclear grading of primary pulmonary adenocarcinomas: correlation between 
nuclear size and prognosis. Cancer 2010;116:2011-9. (9) Tsutani Y, et al. Prognostic 
significance of using solid versus whole tumor size on high-resolution computed 
tomography for predicting pathologic malignant grade of tumors in clinical stage IA 
lung adenocarcinoma: a multicenter study. J Thorac Cardiovasc Surg 2012;143:607-12. 
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INVASIVE MUCINOUS CARCINOMA AND ENTERIC TYPE  
ADENOCARCINOMA
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A new histological classification of lung adenocarcinoma, the IASLC/ATS /ERS 
classification, has been proposed (1). Here we discuss about tumors with mucin 
production, which include 
(i) adenocarcinoma in situ (AIS), mucinous, 
(ii) minimally invasive adenocarcinoma, mucinous, 
(iii) solid adenocarcinoma with mucin production, 
(iv) invasive mucinous adenocarcinoma (formerly mucinous BAC), 
(v) colloid adenocarcinoma, 
(vi) enteric type adenocarcinoma, and 
(vii) invasive adenocarcinoma (here we consider lepidic-, acinar-, papillary- and 
micropapillary-predominant types) with mucin production. It is rare that signet-ring 
adenocarcinoma is composed entirely of signet-ring cells, so the entity is included to 
one of the above types with description of presence of signet-ring cells. It is sensible 
that we classify lung adenocarcinoma with or without TTF-1 expression, because 
adenocarcinomas with TTF-1 expression are probably derived from type II pneumocyte 
precursor cells whereas TTF-1 negative tumors seem to differentiate apart from the 
lineage. In other words, TTF-1 positive tumors develop maintaining lung cell natures 
and TTF-1 negative ones develop loosing such natures. However, adenocarcinoma with 
mucin production is heterogeneous, some being TTF-1 positive and others negative. 
Therefore, we need to develop more appropriate classification of adenocarcinoma 
with mucin. In this lecture, we discuss invasive mucinous adenocarcinoma (formerly 
mucinous BAC) and enteric type adenocarcinoma. Almost all of tumors called mucinous 
BAC previously turned out to be invasive, so the new classification introduced the 
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term “invasive mucinous adenocarcinoma” for this lung-specific tumor. Histological 
characteristics as well as relations to mucinous AIS will be discussed. Enteric type 
adenocarcinoma was first reported by Tsao et al (2), followed by our examination of 7 
cases. After detailed characterization, we may be able to diagnose this entity without 
knowledge of colon cancer history. 
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It has become evident that anaplastic lymphoma kinase (ALK) signaling is activated by 
unique oncogenic fusions of the ALK gene with various partners through chromosomal 
inversion or translocation, resulting in the generation of oncogenic ALK fusion genes 
and their encoded proteins. In 2007, echinoderm microtubule-associated protein–like 
4 (EML4)-ALK, a novel fusion gene generated as a result of an inversion in chromosome 
2 that juxtaposes the 5’ end of the EML4 gene with the 3’ kinase domain of ALK gene, 
was described in non-small cell lung cancer (NSCLC). The fusion gene, EML4-ALK, 
permits constitutive activation of ALK and induces oncogenic cell transformation both 
in vivo and in vitro. ALK-rearranged NSCLC is a unique subset that was characterized 
by younger age, non-smokers, adenocarcinoma histology and was mutually exclusive 
from other well-known oncogenic mutations including EGFR or KRAS. A novel ALK 
tyrosine kinase inhibitor, crizotinib, was approved in 2011 and early studies have shown 
excellent clinical responses in patients with ALK-rearranged NSCLC assessed using 
fluorescence in situ hybridization (FISH). Detection of ALK gene fusions is currently 
indicated as a predictive marker of treatment response to small molecule inhibitors 
of ALK in NSCLC. The overall incidence of ALK gene rearrangements in NSCLC is 
low (<5%); however, is significantly higher in adenocarcinomas with further notable 
predilection for acinar and solid histologic subtypes with signet-ring features. Higher 
rates of ALK rearrangement are encountered in never/light smokers while discordant 
findings are reported in relation to age, gender, and stage. In this period of personalized 
medicine, the ability to accurately identify patients for ALK rearrangement is crucial 
for appropriate treatment and outcome assessment. Pathologists will play a key role in 
the identification of aberrations of ALK in NSCLC. Since the clinical and demographic 
features of the ALK-enriched patients group is overlapped with EGFR-mutated NSCLC, 
the establishment of strategies for identification of ALK-rearranged lung cancer has been 
of great clinical interest and become a critical issue. Studies so far have indicated a need 
to improve stratification of these patients to guide the most appropriate specific therapies 
in small biopsy samples and other routine anatomic pathology pulmonary specimens 
such as cytology cell blocks and touch preparations. Currently, fluorescent in situ 
hybridization (FISH) and immunohistochemistry (IHC) are commonly used to detect 
the ALK rearrangement. The majority of clinical trials examining ALK rearrangement 
have used FISH. In the USA, prescription of crizotinib is dependent on the use of the 
Vysis ALK break apart FISH probe kit (Abbott Molecular, Inc.). Although FISH can be 
performed on formalin-fixed, paraffin-embedded tissue (FFPE) tumor specimens and 
detect multiple ALK fusion variants, there are various challenges related to the FISH 
methods. Scoring of a minimum of 50 tumor cells is recommended and a specimen is 
considered positive for ALK rearrangement when >15% of the cells show break-apart 
signals or isolated red (3’ ALK) signals. However, because the EML4 and ALK loci are 
mapped relatively close on 2p, the interpretation of a positive rearrangement can be 
challenging. In addition, the proportion of positive cells within an ALK-positive tumor 
has been reported to show a broad range greater than 15% but under 100% (range 
22%-87%) and non-neoplastic cells showed FISH positive signals up to 11%. Therefore 
it is recommended that analyses must be performed by experienced pathologist and a 
2-person scoring approach be adopted when the percentage of positive cells is close to the 
cut-off due to the subtle nature of some positive cases. Detection of ALK overexpression 
by IHC has been largely investigated. Early on, the mouse monoclonal anti-human 
CD246 (clone ALK1; Dako) antibody, utilized for evaluation of ALK expression in 
anaplastic large cell lymphoma and inflammatory myofibroblastic tumors, was found 
to be unreliable in NSCLC. Recently, the mouse monoclonal anti-human antibody 
CD246 (clone 5A4; Novocastra) and the rabbit monoclonal anti-human CD246 (clone 
D5F3; Cell Signaling Technology) have been shown to detect ALK fusion protein in lung 
adenocarcinomas with very high sensitivity and specificity. As ALK immunoreactivity 
shows heterogeneous staining pattern, the scoring system including the intensity and 
frequency of staining to assign semiquantitative scores (0 to 3+) improves the positive 
predictive value of ALK FISH results. In this session, the author will present results 
indicating that ALK IHC scoring is a robust measure of the protein overexpression to 
predict ALK rearrangement and might be useful in selecting lung cancers for specific 
targeted therapy. The ALK IHC scoring can be especially helpful in assessing diagnosis in 
a range of settings, for instance, in patients with adenocarcinoma histology and never-
smokers to minimize tissue loss by repeated genetic analysis in the small biopsy samples. 
In addition, the author will discuss discordant ALK status between primary NSCLC and 
their corresponding metastatic lesions. For optimal ALK mutation testing in NSCLC, 
the quality of the tissue sample, the laboratory procedure and the interpretation of the 
results are crucial. 
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Epidermal Growth Factor Receptor (EGFR) is an established therapeutic and prognostic 
biomarker in lung adenocarcinoma. The discovery of EGFR activating mutations in 
patients with response to EGFR-TKI has provided new insights into lung carcinoma 
biology. Adenocarcinoma driven by EGFR mutations occurs predominantly in never-
smokers and women, more frequently in Asians than other ethnical groups. EGFR 
mutations occur early in the adenocarcinoma progression and are frequently observed 
in atypical adenomatous hyperplasia and adenocarcinoma in situ. Histological subtypes 
of invasive adenocarcinoma most frequently associated with EGFR mutations include 
lepidic, papillary and micropapillary, although EGFR mutations can be detected in other 
subtypes. In contrast, EGFR copy number changes occur late in invasive adenocarcinoma 
and are exceptionally rare in precursor lesions. Even though amplification of the mutant 
EGFR allele is very common, no strong correlation between EGFR amplification and 
adenocarcinoma subtype was observed. It has become recognized that the correlation of 
EGFR amplification with EGFR-TKI response is inferior to this strong association with 
EGFR mutation. EGFR-TKI response rates for EGFR amplified, non-mutant cases are 
low, while EGFR mutant cases without amplification show response rates comparable 
to EGFR mutant cases overall. Altogether, reported studies indicate that the EGFR copy 
number change status is less predictive of the patient’s response to EGFR-TKI than EGFR 
mutation. Recently published data suggested that EGFR copy number changes may be a 
modifier of benefit in the setting of EGFR mutation. Heterogenous distribution of EGFR 
mutations has been suggested as a possible cause of resistance or partial response to 
treatment with EGFR-TKI. Earlier reports demonstrated discordant mutation patterns 
between primary and metastatic tumors and heterogeneous distribution of EGFR 
mutation within the primary tumor. This is most likely a result of use of less sensitive 
mutation detection methods. The issue of mutation heterogeneity , which is of clinical 
significance, has been recently resolved. It was demonstrated that EGFR mutations 
within primary tumors are homogenous. Besides methodology and techniques, reported 
heterogeneity of EGFR mutations can be explained by heterogeneous distribution of 
EGFR amplification and mutant-allele specific imbalance. Patients with EGFR-mutated 
lung cancers who initially show a marked response to EGFR-TKI treatment eventually 
demonstrate disease progression during the treatment due to resistance mutations such 
as the secondary mutation T790M and MET amplification. In summary, routine clinical 
testing of lung adenocarcinoma for the presence of EGFR mutations is a standard of 
care. EGFR mutations are predictive of tumor response to EGFR-TKI and are associated 
with improved progression free survival, but not overall survival. A role of EGFR copy 
number changes in response to EGFR-TKI is still undefined. 
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